Actinogen Medical reported steady progress in its Phase 2b/3 XanaMIA trial for Alzheimer’s disease, with topline results expected in November 2026. The trial is fully enrolled with 247 participants, and an independent safety review has approved continuation without changes. The company also has strong patient participation in an open-label extension to gather longer-term data. With $16.7 million in cash, Actinogen is funded into mid-2027, supported by potential tax rebates and option exercises. Positive depression trial data further validate their drug Xanamem. The November readout is a key upcoming catalyst that could validate Xanamem as a once-daily oral treatment for mild to moderate Alzheimer’s, advancing regulatory and commercial prospects.
Mohawk Industries reported a net profit of $196 million and earnings per share of $3.22 for Q2 2026, surpassing expectations due to higher volumes, favorable pricing, and an improved product mix. Net sales rose 6.8% to $3 billion compared to the prev...
Mohawk Industries announced a net profit of $196 million and earnings per share (EPS) of $3.22 for Q2 2026, showing significant growth from the previous year. Revenue rose 8% to $3.0 billion, driven by volume growth, pricing strategies, and product m...
Mohawk Industries reported a net income of $196 million and earnings per share (EPS) of $3.22 for Q2 2026, surpassing market expectations. Sales increased 6.8% to $3 billion, driven by higher volumes, pricing, and product range expansion despite a we...
Ares Capital Corporation (ARCC) has been downgraded to HOLD due to valuation concerns, despite its strong credit management and leadership in the sector. The company's net investment income per share has declined to $0.50, and non-accrual loans have ...
Solana's price remains range-bound near $73 despite softer trading volume, supported by ongoing ecosystem developments like Rarible's NFT marketplace relaunch and a payment integration pilot with KSNET in South Korea. Institutional interest grows as ...
